Key result
Hormone replacement normalizes severe QT prolongation, reducing QTc by ~157 ms in panhypopituitarism.
Why the study?
Does hormonal replacement therapy improve QT prolongation in a patient with panhypopituitarism?
Case Report (n=1)
No
Does hormonal replacement therapy improve QT prolongation in a patient with panhypopituitarism?
Hormonal disorders such as panhypopituitarism should be considered as a potential cause of long QT intervals, which can be reversed with appropriate hormone replacement therapy.
Answers are grounded in this paper and cite their sources.
Hormone replacement may normalize QT prolongation in panhypopituitarism; hypothesis-generating for endocrine causes of long QT.
We describe a 37-year-old patient with panhypopituitarism who experienced symptoms and signs of hormonal insufficiency and QT prolongation on electrocardiogram without electrolyte disturbances. After hormonal (steroidal and thyroid) replacement therapy electrocardiographic findings were normalized. Hormonal disorders should be considered as a cause of long QT intervals which may lead to torsade de pointes, even if plasma electrolyte levels are normal, because life-threatening arrhythmia is treatable by supplementation of the hormone that is lacking.
No takes yet. Share an insight, caveat, or question.
Arpacı et al. (2013) conducted a case report in QT prolongation associated with panhypopituitarism (n=1). Steroid and thyroid hormone (levothyroxine) replacement therapy was evaluated on QT/QTc interval normalization on electrocardiogram. Steroid and thyroid hormone replacement normalized the prolonged QT/QTc interval from a maximal 549 ms to 364/392 ms within 3 weeks in a 37-year-old woman with panhypopituitarism.
Synapse has enriched 10 related papers. Consider them for comparative context: